Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
VOR Biopharma's valuation surged after in-licensing telitacicept and securing PIPE financing, but capital structure uncertainty persists. Telitacicept's positive phase 3 data in Sjögren's disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback